JHVEPhoto/iStock Editorial via Getty Images
- Johnson & Johnson (NYSE:JNJ) is set to release its Q3 2021 earnings results before the bell on Tuesday.
- The consensus EPS estimate is $2.38. For Q2, the estimate was $2.29 and J&J reported $2.48. J&J also beat on revenue and raised its 2021 guidance.
- J&J's stock return for the quarter was -2.1%. That trailed peers Pfizer, Eli Lilly, and Pfizer, but was ahead of Bristol-Myers Squibb and Merck.
Q3 News Highlights
- Late last month, J&J began a phase 3 trial of its respiratory syncytial virus ("RSV") candidate.
- In mid-September, the company made several presentations at the European Society for Medical Oncology ("ESMO") Annual Congress 2021. Among them was Balversa (erdafitinib) in bladder cancer.
- On Sept. 1, Invega Hayfera (paliperidone palimitate) was approved as a twice a year antipsychotic for schizophrenia.
- CEO Alex Gorsky announced in August he would step down with Joaquin Duato taking the reins beginning on Jan. 3, 2022.
- In July, J&J finalized a settlement with state attorney generals over the opioid epidemic, agreeing to pay $5B.